Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Clotrimazole + betamethasone** is a topical combination drug consisting of clotrimazole, an imidazole-class antifungal, and betamethasone, a synthetic corticosteroid. The antifungal component inhibits fungal growth by disrupting cell membrane synthesis, while the corticosteroid reduces inflammation by suppressing various mediators of the immune response. This drug is indicated primarily for fungal skin infections—such as tinea corporis (ringworm), tinea cruris (jock itch), and tinea pedis (athlete's foot)—particularly when accompanied by significant inflammation[1][2][3][7][10]. It is not effective against bacterial or viral infections. The combination is supplied predominantly as a topical cream or lotion and is intended for short-term use due to the risk of corticosteroid-related adverse effects[2][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clotrimazole + betamethasone.